IdentifAI Genetics

Identifai Genetics is developing a noninvasive prenatal test for the early detection of single-gene disorders. Using a simple first-trimester maternal blood test to access the entire embryonic genome, Identifai can perform a comprehensive analysis capable of detecting every single-point mutation, insertion-deletion, and structural variation in order to identify severe genetic disorders. Identifais core suite of algorithms, the Hoobari paradigm, is a patent-pending proprietary methodology developed for five years at Tel Aviv University. The technology has demonstrated high accuracy in detecting a wide variety of mutations in real-life cases, and the company is planning to launch clinical studies. Identifai Genetics is dedicated to providing solutions that will enable safe pregnancies for all families, everywhere.

IdentifAI Genetics has raised $9.25M in total funding across 6 rounds. The company is currently at the Seed stage. Key investors include eHealth Ventures, Undisclosed Investor(s), Shizim Group.

IdentifAI Genetics was founded in 2020 by Yossi Bornstein (Chairman), Noam Shomron (Co-founder & CSO), Oren Tadmor (Co-founder & Head of Product).

IdentifAI Genetics operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Test Diagnostics & Screening, with core technologies in Biologicals, Genes, Artificial Intelligence, Machine Learning, Deep Learning. Target customers: Healthcare & Life Sciences, Healthcare, Insurance Companies, Laboratories, Patients, Providers, Life Sciences, Biotechnology.

IdentifAI Genetics is based in HaMelacha Street 22, Rosh Haayin, Israel, Center District.